ABIOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:51):

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases...

Stats
本日の出来高	171 395
平均出来高	1.45M
時価総額	49.59M
EPS	$0 ( 2024-04-24 )
次の収益日	( $0 ) 2024-07-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.24
ATR14	$0.0150 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Ma-weaver Jacob	Buy	6 000	Stock option (right to buy)
2024-01-30	Hove Anders D	Buy	6 000	Stock Option (right to buy)
2024-01-30	Mitchell Daniel J	Buy	6 000	Stock Option (right to buy)
2024-01-30	Flynn James P	Buy	6 000	Stock Option (right to buy)
2024-01-30	Conway Robert E	Buy	6 000	Stock Option (right to buy)

INSIDER POWER
98.21
Last 95 transactions
Buy: 2 938 848 \| Sell: 17 694 644

ボリューム相関

長: -0.13 (neutral)

短: 0.83 (strong)

Signal:(22.164) Same movement expected

ARCA Biopharma Inc 相関

10 最も正の相関
AMRB	0.928
SQQQ	0.923
SGH	0.909
SBNYP	0.909
PMVP	0.909
XPEL	0.907
SPRB	0.903
SMTC	0.899
ALDX	0.895
WTBA	0.891

10 最も負の相関
AMD	-0.923
PRVB	-0.92
QQQM	-0.918
QQQ	-0.918
OSIS	-0.918
CIFR	-0.916
CYN	-0.915
NVEI	-0.913
DRNA	-0.912
SMH	-0.911

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ARCA Biopharma Inc 相関 - 通貨/商品

0.20
( neutral )

-0.34
( neutral )

0.00
( neutral )

-0.05
( neutral )

-0.14
( neutral )

-0.36
( neutral )

ARCA Biopharma Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2023
収益:	$0
総利益:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2022
収益:	$0
総利益:	$-114 000 (0.00 %)
EPS:	$-0.640

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.390

Financial Reports:

No articles found.

ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.